

Termination of Coverage

*April 1, 2024**Dawson James Securities, Inc.
Senior Management
Compliance@dawsonjames.com*

Effective immediately, Dawson James Securities, Inc. has terminated research coverage of the following companies as a result of the analyst covering each company is no longer employed by Dawson James. The rating and date of the last report are shown below adjacent to the closing price of March 28, 2024, in the format (Date of last report/Last rating). Copies of the referenced prior reports may be accessed on our website at: [Reports Landing Page – Dawson James](#)

Research on the following companies is being terminated as the covering analyst is no longer employed by Dawson James. The rating and date of the last report are shown below adjacent to the closing price of March 28, 2024, in the format (Date of last report/Last rating/3/28/24 closing price):

- Aditxt Therapeutics (ADTX) – Company Update; 1/10/24; Neutral; \$3.40
- Arch Therapeutics (ARTH) – Company Update 11/27/23; Neutral; \$1.96
- Anavex Life Science Corp. (AVXL) - Company Update 2/28/24; Buy; \$5.09
- BioCardia, Inc. (BCDA) - Company Update 2/12/24; Neutral; \$0.41
- HeartBeam, Inc. (BEAT) – Company Update 11/16/23; Buy; \$2.18
- Bluejay Diagnostics, Inc. (BJDX) - Company Update 12/29/23; Neutral; \$0.80
- Can-Fite BioPharma Ltd. (CANF) -Company Update 1/29/24; Buy; \$2.22
- Check Cap Ltd. (CHEK) - Company Update 12/27/23; Neutral; \$3.11
- CollPlant Biotechnologies Ltd. (CLGN) - Company Update 11/29/23; Buy; \$5.35
- Citius Pharmaceuticals, Inc. (CTXR) - Company Update 2/15/24; Buy; \$0.90
- Cytosorbents Corporation (CTSO) – Price Target Change 12/28/23; Buy; \$0.95
- Dare Bioscience, Inc. (DARE) - Company Update 2/23/24; Neutral; \$0.49
- Fortress Biotech, Inc. (FBIO) – Price Target Change 11/13/23; Buy; \$2.00
- Genprex, Inc. (GNPX) - Company Update 2/6/24; Neutral; \$2.98
- GeoVax Labs, Inc. (GOVX) – Company Update 3/1/24; Buy; \$2.00
- Tharimmune, Inc. (THAR) Formerly Hillstream (HILS) – Company Update 1/23/24; Neutral; \$0.43
- Know Labs, Inc. (KNW) – Company Update 3/7/24; Neutral; \$0.63
- Kintara (KTRA) – Company Update 2/13/24; Neutral; \$0.10
- Lineage Cell Therapeutics (LCTX) – Company Update 3/12/24; Buy; \$1.48
- NRx Pharmaceuticals, Inc. (NRXP) – Company Update 3/6/24; Buy; \$0.47
- Smart for Life, Inc. (SMFL) – Company Update 1/25/24; Neutral; \$0.62
- Tonix Pharmaceuticals Holding Corp. (TNXP) – Company Update 3/11/24; Buy; \$0.19
- Zomedica Copr. (ZOM) – Company Update 3/8/24; Neutral; \$0.15
- Cemtrex, Inc. (CETX) – Company Update 2/16/24; Buy; \$4.19

Effective upon this termination of coverage, investors should no longer rely on any of our prior research, financial estimates, or ratings for these companies.

Important Disclosures:

Latest company updates with ratings and target, if applicable:

- Aditxt Therapeutics (ADTX) – Company Update; 1/10/24; Neutral
- Arch Therapeutics (ARTH) – Company Update 11/27/23; Neutral
- Anavex Life Science Corp. (AVXL) - Company Update 2/28/24; Buy; \$39.00
- BioCardia, Inc. (BCDA) - Company Update 2/12/24; Neutral
- HeartBeam, Inc. (BEAT) – Company Update 11/16/23; Buy; \$6:00
- Bluejay Diagnostics, Inc. (BJDX) - Company Update 12/29/23; Neutral
- Can-Fite BioPharma Ltd. (CANF) -Company Update 1/29/24; Buy; \$6:00
- Check Cap Ltd. (CHEK) - Company Update 12/27/23; Neutral
- CollPlant Biotechnologies Ltd. (CLGN) - Company Update 11/29/23; Buy; \$17.00
- Citius Pharmaceuticals, Inc. (CTXR) - Company Update 2/15/24; Buy; \$8:00
- Cytosorbents Corporation (CTSO) – Price Target Change 12/28/23; Buy; \$4.00
- Dare Bioscience, Inc. (DARE) - Company Update 2/23/24; Neutral
- Fortress Biotech, Inc. (FBIO) – Price Target Change 11/13/23; Buy; \$10.00
- Genprex, Inc. (GNPX) - Company Update 2/6/24; Neutral
- GeoVax Labs, Inc. (GOVX) – Company Update 3/1/24; Buy; \$5.00
- Tharimmune, Inc. (THAR) Formerly Hillstream (HILS) – Company Update 1/23/24; Neutral
- Know Labs, Inc. (KNW) – Company Update 3/7/24; Neutral
- Kintara (KTRA) – Company Update 2/13/24; Neutral
- Lineage Cell Therapeutics (LCTX) – Company Update 3/12/24; Buy; \$2.00
- NRx Pharmaceuticals, Inc. (NRXP) – Company Update 3/6/24; Buy; \$2.00
- Smart for Life, Inc. (SMFL) – Company Update 1/25/24; Neutral
- Tonix Pharmaceuticals Holding Corp. (TNXP) – Company Update 3/11/24; Buy; \$3.00
- Zomedica Copr. (ZOM) – Company Update 3/8/24; Neutral
- Cemtrex, Inc. (CETX) – Company Update 2/16/24; Buy; \$11.00

Dawson James Securities, Inc. (the “Firm”) is a member of the Financial Industry Regulatory Authority (“FINRA”) and the Securities Investor Protection Corporation (“SIPC”).

The Firm does not make a market in the securities of the subject companies. The below chart reflects important disclosures for Investment Banking and other compensation as well as firm ownership of 1% or more.

Company Name	Symbol	Has Engaged in Investment Banking in the Last 12 Months	Has Received Other Compensation in the Last 12 Months	Firm Ownership of 1% or more of outstanding shares
Anavex Life	AVXL	No	No	No
Biocardia Inc.	BCDA	No	No	No
Can Fite Bio	CANF	No	No	No
Cemtrex, Inc.	CETX	No	No	No
Check-Cap Ltd.	CHEK	No	No	No
Citius Pharma	CTXR	No	Yes	No
Collplant Bio	CLGN	No	No	No
Cytosorbents Corp.	CTSO	No	Yes	No
Dare Bio	DARE	No	No	No

Kintara Therapeutics, Inc. (KTRA) Formerly DMPI	KTRA	No	Yes	No
Fortress Biotech	FBIO	No	No	No
Lineage Cell	LCTX	No	No	No
Aditxt Therapeutics, Inc.	ADTX	No	Yes	No
Arch Therapeutics	ARTH	Yes	No	No
Bluejay diagnostics	BJDX	No	No	No
Know Labs, Inc. (Former Symbol (KNWN))	KNW	No	Yes	No
Heartbeam, Inc.	BEAT	No	Yes	No
Smart for Life, Inc.	SMFL	No	No	No
Zomedica Corp.	ZOM	No	Yes	No
Genprex, Inc.	GNPX	No	Yes	No
Tharimmune (THAR) Formerly Hillstream BioPharma (HILS)	THAR	No	Yes	No
GeoVax Labs, Inc.	GOVX	Yes	Yes	No
NRx Pharmaceuticals, Inc.	NRXP	No	No	No
Tonix Pharmaceuticals Holding Corp.	TNXP	No	No	No

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of March 28, 2024, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable but cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

Ratings Definitions:

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months;
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months;
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Current as of March 28, 2024

	Company Coverage		Investment Banking	
Ratings Distribution	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	0	0%	0	0%
Market Perform (Neutral)	0	0%	0	0%
Market Underperform (Sell)	0	0%	0	0%
Total	0	0%	0	0%

